Targeting the Ras palmitoylation/depalmitoylation cycle in cancer.

Abstract excerpt

The Ras proteins are well-known drivers of many cancers and thus represent attractive targets for the development of anticancer therapeutics. Inhibitors that disrupt the association of the Ras proteins with membranes by blocking the addition of the farnesyl lipid moiety to the Ras C-terminus failed in clinical trials. Here, we explore the possibility of targeting a second lipid modification, S-acylation, commonly...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acyltransferases
• Share to Carcinogenesis
• Share to Cysteine